AbbVie (ABBV) Raises 2026 Outlook After Q1 EPS and Revenue Beat

AbbVie Inc. (NYSE: ABBV) climbed $6.20, or 3.14%, to $203.89 on Tuesday after the drugmaker reported Q1 2026 results that exceeded expectations and raised its full-year outlook. The advance reflected investor confidence in the company's immunology franchise, which continues to offset an ongoing decline in legacy products.

Q1 2026 At a Glance

• EPS of $2.65 beat consensus estimates, confirmed in the April 29, 2026 8-K filing (Results of Operations, Item 9.01)
• Revenue of $15 billion surpassed analyst expectations on a year-over-year basis
• 2026 EPS guidance raised to $14.28, up from the prior outlook
• Revenue growth (YoY): 10.0%, reflecting continued top-line momentum
• Gross margin: 71.6% and operating margin: 34.1%, underlining the company's cost efficiency
• Net margin: 6.9%, reflecting heavier below-the-line charges typical of large-cap biopharma
• 52-week range: $176.57 – $244.81; current price of $203.89 sits in the lower half of that band

What Drove the Results

Skyrizi and Rinvoq, AbbVie's next-generation immunology therapies, were the primary growth engines in the quarter. Their combined commercial performance was sufficient to more than compensate for continued revenue erosion from Humira — which faces biosimilar competition — and Imbruvica, a hematology asset in structural decline.

The strength of the immunology portfolio also supports the company's high gross margin profile. With a forward P/E of 12.7x against a trailing P/E of 86.0x, the valuation gap signals that the market is pricing in a significant earnings recovery as the Humira headwind fades and newer products scale — though the trailing multiple reflects near-term margin compression rather than underlying business deterioration.

Wall Street View

Analyst sentiment on AbbVie (NYSE: ABBV) remained firmly constructive heading into the print. As of April 1, 2026, the consensus stood at 7 Strong Buy, 21 Buy, and 11 Hold, with zero Sell or Strong Sell ratings. Compared to the March 1 snapshot — 7 Strong Buy, 20 Buy, 12 Hold — one analyst upgraded from Hold to Buy, a modest but directionally positive shift that preceded the Q1 beat.

Investor Takeaway

AbbVie's Q1 2026 results and upward guidance revision underscore that its immunology transition is on track, with Skyrizi and Rinvoq absorbing the Humira revenue gap more effectively than some had anticipated. The combination of 10.0% revenue growth, a 71.6% gross margin, and a raised $14.28 EPS outlook gives the analyst community a concrete basis for its predominantly Buy-rated consensus. Investors will likely focus on the pace of Skyrizi and Rinvoq penetration in upcoming quarters as the key indicator of whether full-year guidance proves conservative or directionally accurate.